Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877694 | 0.84 | SMN1; SMN2 (0.46) | OGACYP1A2CYP2C19ALOX15SMN1; SMN2 | |
| SCHEMBL937322 | 0.84 | SMN1; SMN2 (0.50) | OGACYP1A2CYP2C19ALOX15SMN1; SMN2 | |
| SCHEMBL2570788 | 0.82 | SMN1; SMN2 (0.53) | OGACYP1A2SMN1; SMN2NPC1TSHR | |
| SCHEMBL5122657 | 0.81 | OGA (0.43) | OGACYP1A2CYP2C19ALOX15SMN1; SMN2 | |
| SCHEMBL4937062 | 0.79 | BPTF (0.51) | CYP1A2CYP2C19HRH4 | |
| SCHEMBL2570384 | 0.79 | CYP2C19 (0.58) | OGACYP1A2CYP2C19SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL4818046 | 0.78 | BPTF (0.50) | CYP1A2CYP2C19HRH4 | |
| SCHEMBL6894413 | 0.78 | OGA (0.44) | OGACYP1A2CYP2C19ALOX15SMN1; SMN2 | |
| SCHEMBL16854339 | 0.77 | HTR3E (0.53) | OGACYP1A2ALOX15TSHRHRH4 | |
| SCHEMBL16894257 | 0.77 | OGA (0.43) | OGACYP1A2CYP2C19ALOX15LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108613-B | Bromodomain inhibitors and uses thereof | 基因泰克公司 | 2020-02-25 | — | — | CN | disclosed |
| CN-107108613-A | Bu Luomo domain inhibitor and application thereof | 基因泰克公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-103214414-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-101263110-B | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| CN-1745071-A | Novel ethylenediamine derivative | DAIICHI SEIYAKU CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | OGA 3890/4885CYP1A2 1707/4885CYP2C19 257/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | OGA 4669/4885CYP1A2 3257/4885CYP2C19 1910/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | OGA 4589/4885CYP1A2 2631/4885CYP2C19 1616/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | OGA 4589/4885CYP1A2 2631/4885CYP2C19 1616/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | OGA 4589/4885CYP1A2 2631/4885CYP2C19 1616/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | OGA 1224/4885CYP1A2 2267/4885CYP2C19 1344/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | OGA 4625/4885CYP1A2 2535/4885CYP2C19 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.